The Life Sciences Innovation Day brings together leaders from academia and industry (e.g. academic/clinical scientists, biotech & pharma, CROs, SMEs, etc.) to discuss current challenges and develop new concepts for an ecosystem fostering open science and innovation. In this ecosystem of public-private partnerships, members from academia, industry and society connect, share perspectives, and directly collaborate on high-impact research and development of projects with defined outcomes tangible in the public sphere.
The specialization of scientific researchers has been essential for developing expertise in many individual fields comprising the biomedical landscape, but the resulting culture of specialty silos has diminished cross-disciplinary collaborations, which are crucial for addressing complex problems that directly impact societal stakeholders. As a consequence, the recognition and trust of the public towards scientists has diminished, research funding has stagnated, while pressing issues in medicine remain unresolved.
In alternating keynote lectures and expert panel presentations, attendees discuss:
- benefits of open science for basic research and drug discovery,
- how new technologies in personalized medicine can have direct impact in society,
- new financial models to enable sustainable research ecosystems,
- new directions for open innovation public-private partnerships
Poster spaces will be provided should you wish to bring a visual aid to enhance 1-2-1 meetings.
ABOUT THE INNOVATION DAY SPEAKERS
Prof. Aled Edwards is CEO at the Structural Genomics Consortium, Professor at the University of Toronto and University of Oxford, and Director of M4K Pharma. The Structural Genomics Consortium is a public-private partnership of leading academic groups and pharmaceutical companies pioneering open science in drug discovery.
Prof. Ruedi Aebersold (ETH Zurich and University of Zurich) is a pioneer in the areas of proteomics and systems biology. His group develops mass spectrometry and computational methods, and applies them to diverse fields in biology and personalized medicine.
Prof. Mark Rubin (University of Bern and Cornell Medical College, New York) is a recognized leader in the areas of prostate cancer genomics and pathology. He is the Founding Director of the Englander Institute of Precision Medicine and also leading the development of a new Center for Precision Medicine in Bern.
Prof. Effy Vayena (ETH Zurich) is a recognized leader in the fields of ethical and policy challenges in precision medicine and digital health.
Wen Hwa Lee
Dr. Wen Hwa Lee recently joined the charity Action Against Age-Related Macular Degeneration. He is co-director of the Affordable Medicines Program at the Oxford Martin School and served the Structural Genomics Consortium as the director of the Disease Foundations Network.
Dr. Hans Widmer is the Program Director for Industry-Academia Liaison at the Novartis Institutes for BioMedical Research in Basel, Switzerland.
Dr. Johannes Mosbacher is the Business Interface Officer at the Roche Innovation Center in Basel, Switzerland.
Prof. Roland Martin (University Hospital Zurich and University of Zurich) heads the section Neuroimmunology and Multiple Scerosis Research at the University Hospital Zurich. He is an internationally-recognized expert in neurology, core faculty of the Wyss Translational Center Zurich, a cofounder of the Drug Discovery Network Zurich (DDNZ), a cofounder of the Therapy Development Accelerator (TDA) at the University Zurich, and a cofounder and co-owner of Cellerys AG, a startup company specializing in tolerance induction.
Prof. Ernst Hafen leads a research group in systems genetics at ETH Zurich. He is a co-founder and president of the citizen science platform MIDATA.coop and serves as the president of the Bio-Technopark Zürich-Schlieren.
Prof. Peter Wild (Frankfurt University Hospital) is the director of the Senckenberg Institute of Pathology at the University Hospital Frankfurt. His group applies genomics, proteomics and image-based tissue phenomics to identify clinically significant biomarkers for cancer and their implications for prognosis, therapy response, and classification of the disease.
Daniel Vonder Mühll
Dr. Daniel Vonder Mühll is the Executive Director of Personalized Health and Related Technologies (PHRT), a strategic focus area of the ETH domain.
Dr. Jones is an Associate Editor at the open access journal Nature Communications.
Prof. Lawrence Rajendran leads a research group on systems and cell biology of neurodegeneration at the University of Zurich. He is also the founder and CEO of Science Matters, the next generation open-access and open science journal platform.
Laura de Vargas
Dr. Laura de Vargas (University of Zurich, Bare-Science) is an expert in novel publishing strategies and application of single cell technologies and big data for personalized medicine. She is a co-founder of the platform Bare-Science.
Servan Grüninger is co-founder and president of the think tank reatch.